TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
ADAURA - D5164C00001
Phase 3 small_molecule active
Quick answer
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO for Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active